{
    "paper_id": "PMC7105179",
    "metadata": {
        "title": "Anticorps monoclonaux : tours et d\u00e9tours technologiques pour de nouveaux espoirs th\u00e9rapeutiques",
        "authors": [
            {
                "first": "Dominique",
                "middle": [],
                "last": "Bourel",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jean-Luc",
                "middle": [],
                "last": "Teillaud",
                "suffix": "",
                "email": "jean-luc.teillaud@u255.bhdc.jussieu.fr",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Since their discovery by K\u00f6hler and Milstein thirty years ago, monoclonal antibodies (mAbs) have been intensively engineered to optimize their functional properties, to reduce their immunogenicity and to increase their clinical efficacy. Because the vast majority of mAbs in the early 1980s was of rodent origin, human anti-mouse antibodies (HAMAs) were induced when mAbs were infused to patients. Such HAMAs hamper the therapeutic efficacy of mAbs and provoke side effects related to the formation of immune complexes. In addition, the effector functions and the pharmacokinetic properties of mouse antibodies are markedly lowered in humans. Moreover, binding of murine IgG mAbs to the human neonatal FcRn, which rescues IgG from degradation and, hence, increases their serum half-life, is also weaker. Thus, many efforts have been devoted to generate human antibodies using both cellular and molecular engineering.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "No technology was available in the late 1970s to generate fully human antibodies, except the infection of human B lymphocytes by the Epstein\u2013Barr virus (EBV), which allowed the generation of immortalized B cells producing mAbs. However, this method has been limited by formidable problems such as the selection of antibodies with the desired antigen specificity, cell-line stability and the limited amount of antibodies produced for a therapeutic use. Other approaches based on cellular engineering (such as optimized fusion partners or long-term growth of human B lymphocytes) were shown to be poorly efficient or difficult to set up. Thus, molecular engineering of mAbs rapidly developed in the early 1980s and has been the leading force for antibody engineering since then, although cellular engineering has made recently a remarkable comeback: the transformation of memory B cells by EBV from virus-infected patients and their stimulation with CpG (which triggers TLR9-mediated B-cell proliferation) allow the generation of a large number of EBV-transformed cell lines that produce high-affinity specific IgG mAbs.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "The development of molecular engineering techniques based on a better knowledge of immunoglobulin gene organization and of immunoglobulin 3-D structure allowed the engineering of chimeric antibodies and humanized antibodies. Chimeric antibodies comprise the variable domains derived from rodent mAbs fused to the constant domains of human heavy and light chains. Five chimeric mAbs are on the market. Humanized antibodies are obtained by grafting complementarity-determining regions (CDRs) derived from murine antibodies with desired specificity onto carefully chosen human VH and VL frameworks (FRs). The human FRs are selected on the basis of structural models of the variable domains of the mouse parental antibodies. However, the humanization technology does not work for each mouse antibody, as a strong decrease in antibody affinity or a loss of antigen binding of the resulting humanized variable domains can be observed in some cases. Nevertheless, this approach has proved to be powerful, as seven humanized mAbs are currently on the market. An elegant technique for generating fully human antibodies has been the adaptation of the filamentous phage display technique to the expression of antibody fragments. It allowed the establishment of large combinatorial libraries of human VH and VL and made it possible to select for specific Fab' or single-chain Fv (scFv) fragments that are then used to build a whole recombinant human mAb. Last, techniques that allow gene inactivation and insertion of large human DNA fragments from yeast artificial chromosome in mouse germline have made it possible to generate transgenic mice capable of producing fully human antibodies following immunization. An alternative to this approach is the generation of double trans-chromosomic (Tc) mice that harbor two individual \u2018mini-chromonosomes\u2019, containing the complete germline loci of immunoglobulin heavy and \u03ba-light chains. Such mice can mount an antigen-specific human antibody response following immunization, and human antigen-specific mAbs can be generated. Two antibodies obtained from phage-display libraries and from humanized mice are on the market and several others are currently being tested in clinical trials. Although only two of the 18 mAbs currently approved and marketed are fully human antibodies, about 20%of the 150 mAbs currently in clinical development are human antibodies derived either from phage-display libraries or from transgenic mice.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "Monoclonal antibodies elicit effector functions following interactions between their Fc region and different Fc receptors (FcRs), as well as with C1q. Most therapeutic mAbs are human IgG1 or have Fc region derived from this isotype, which can efficiently interact with Fc\u03b3Rs. Among Fc\u03b3Rs, the activating Fc\u03b3Rs (Fc\u03b3RI, Fc\u03b3RIIA and Fc\u03b3RIII) induce ADCC, endocytosis of immune complexes followed by antigen presentation, phagocytosis, and/or release of cytokines. The inhibitory Fc\u03b3RIIB regulates immune responses by inhibiting the activation of B lymphocytes, monocytes, mast cells and basophils, induced through activating receptors. Thus, engineering the Fc region of IgG mAbs to improve effector functions is now a major goal. Alteration of residues in the Fc region improves the binding to activating Fc\u03b3R. Some of the mAbs currently developed have been mutated so that the cellular toxicity triggered by Fc\u03b3Rs engagement is strongly increased. Another approach to increase the biological activity of IgG is to engineer the glycosylation pattern of the Fc region. An IgG molecule contains an oligosaccharide covalently attached at the conserved Asn297 of each of the CH2 domains in the Fc region. The IgG glycosylation is essential for effector functions of the molecule. Variations of IgG glycosylation patterns include attachment of terminal sialic acid, a third N-acetylglucosamine arm (bisecting GlcNac), terminal galactosylation and core fucosylation. Engineering IgG glycoforms may lead to an optimized Fc\u03b3RIII-dependent ADCC. Several studies have focused on the role of bisecting GlcNac in binding to Fc\u03b3RIII and ADCC. Other studies have also shown that non-fucosylated oligosaccharides play a critical role in enhancing ADCC. Thus, current studies try to engineer cell lines to produce recombinant IgG with a well-defined pattern of glycosylation in their Fc region.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "Over the last decade, therapeutic antibodies have moved to the forefront of protein drug development, and the coming years will see a new wave of recombinant molecules in a number of indications where efficient drugs are not available. However, therapeutic antibodies still face important challenges. Firstly, examination of the clinical responses shows that only a low percentage of patients exhibits long-lasting complete responses to treatments, particularly in cancer. One can expect that the simultaneous use of therapeutic mAbs that target different cell surface receptors or epitopes of the same receptor, or that target tumor-associated antigens and molecules involved in neo-angiogenesis, might allow to obtain more long-term clinical improvement. Secondly, severe side effects, such as the appearance of tuberculosis or lymphomas, the worsening of heart failure, and increased cardiocytotoxicity when combined with anthracyclin-based chemotherapy, have been described for some mAbs. Thus, there is still a need to enhance the efficacy of these recombinant products and to lower the side effects that are observed. It may be achieved by more molecular engineering to improve the affinity and/or the avidity for the target molecule. In parallel, molecular design of the Fc region will help to recruit either the activating or the inhibitory Fc\u03b3Rs depending of the disorder being targeted or abolishing the binding to these receptors while optimizing the binding to FcRn.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "Finally, one has to point out that one of the most challenging problems of therapeutic mAbs is due to their success, the production at low costs of bulk quantities required for trials and treatments of large cohorts of patients. The generation of new production technologies (yeast, plantibodies, transgenic animals) is clearly an urgent need.",
            "cite_spans": [],
            "section": "Abridged English version",
            "ref_spans": []
        },
        {
            "text": "C'est en 1975 que C\u00e9sar Milstein et Georges K\u00f6hler ont publi\u00e9 dans la revue britannique Nature un article de trois pages d\u00e9montrant qu'il \u00e9tait possible d'obtenir des cellules hybrides, ou hybridomes, produisant des anticorps de sp\u00e9cificit\u00e9 pr\u00e9d\u00e9finie, cellules pouvant se cloner et se cultiver in vitro : les anticorps monoclonaux (AcM) \u00e9taient n\u00e9s [1]. Directement issue de travaux des ann\u00e9es 1960 portant sur la fusion cellulaire et la synth\u00e8se de l'ADN, men\u00e9s notamment par Georges Barski, Boris Ephrussi et John Littlefield, la technique de production des AcM par fusion cellulaire avec des cellules de my\u00e9lome de lymphocytes B provenant de souris immunis\u00e9es fut initialement mise au point pour r\u00e9pondre \u00e0 des questions d'immunologie fondamentale. En effet, les r\u00e8gles gouvernant l'expression, la synth\u00e8se et l'association des cha\u00eenes lourdes (H) et l\u00e9g\u00e8res (L) des anticorps dans les lymphocytes B, ainsi que les relations existant entre sp\u00e9cificit\u00e9 et association H/L \u00e9taient alors mal d\u00e9finies, ce qui conduisit divers immunologistes \u00e0 rechercher de nouveaux outils cellulaires permettant d'explorer ces diff\u00e9rentes questions.",
            "cite_spans": [
                {
                    "start": 350,
                    "end": 353,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "De telles cellules hybrides se multiplient ind\u00e9finiment en donnant naissance \u00e0 des populations de cellules filles identiques entre elles et en fabriquant les anticorps que les lymphocytes B provenant des animaux immunis\u00e9s produisaient. Chaque clone de cellules filles produit le m\u00eame anticorps, qui est dit \u00ab monoclonal \u00bb, un ph\u00e9nom\u00e8ne fond\u00e9 sur le fait qu'un lymphocyte B ne produit qu'un seul type d'anticorps ayant une sp\u00e9cificit\u00e9 donn\u00e9e. On dispose alors d'une source illimit\u00e9e de cellules produisant, au moins en th\u00e9orie, toujours le m\u00eame anticorps ayant la m\u00eame affinit\u00e9 et les m\u00eames propri\u00e9t\u00e9s physico-chimiques.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "La d\u00e9couverte des AcM suscita imm\u00e9diatement de nombreux espoirs th\u00e9rapeutiques. Cependant, alors que des avanc\u00e9es consid\u00e9rables dans le domaine de la recherche fondamentale et dans celui du diagnostique furent faites rapidement, d'importants probl\u00e8mes surgirent lorsque l'utilisation des AcM chez des patients fut envisag\u00e9e. Outre la question de l'obtention d'anticorps de haute affinit\u00e9 dirig\u00e9e contre des cibles sp\u00e9cifiques pertinentes, deux probl\u00e8mes li\u00e9s \u00e0 l'utilisation it\u00e9rative d'un anticorps de souris ou de rat chez l'homme apparurent rapidement : (i) pr\u00e9sence d'anticorps humains anti-anticorps de souris ( \u00ab HAMA \u00bb, pour Human Anti-Mouse Antibody), conduisant \u00e0 une diminution d'efficacit\u00e9 et \u00e0 des effets secondaires ind\u00e9sirables dus \u00e0 la formation de complexes immuns ; (ii) propri\u00e9t\u00e9s effectrices des anticorps de souris inject\u00e9s m\u00e9diocres (malgr\u00e9 l'absence d'une barri\u00e8re d'esp\u00e8ce au sens strict) : les AcM se fixent notamment par leur partie constante (Fc) aux r\u00e9cepteurs pour la r\u00e9gion Fc (RFc) pr\u00e9sents \u00e0 la surface de cellules du syst\u00e8me immunitaire, induisant des m\u00e9canismes effecteurs comme la capture de complexes immuns et la cytotoxicit\u00e9 d\u00e9pendante d'anticorps ( \u00ab ADCC \u00bb, pour Antibody-Dependent Cell Cytotoxicity). Cette fixation est diminu\u00e9e lorsque des anticorps de type IgG de souris sont utilis\u00e9s, conduisant une activation plus faible des cellules effectrices humaines [2].",
            "cite_spans": [
                {
                    "start": 1400,
                    "end": 1403,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Ces probl\u00e8mes ont conduit \u00e0 la fin des ann\u00e9es 1970 \u00e0 l'\u00e9laboration de techniques cellulaires de manipulation des hybridomes in vitro, ainsi qu'au d\u00e9veloppement de techniques cellulaires d'obtention d'anticorps humains. Les manipulations in vitro d'hybridomes ont vis\u00e9 \u00e0 obtenir des anticorps de meilleure affinit\u00e9, ainsi que, suivant leur utilisation th\u00e9rapeutique potentielle, des anticorps ayant des propri\u00e9t\u00e9s effectrices modifi\u00e9es, comme l'absence de fixation aux RFc\u03b3 ou au C1q, premi\u00e8re \u00e9tape de l'activation de la voie classique du compl\u00e9ment, qui aboutit \u00e0 la lyse des cellules cibles. Ces manipulations ont repos\u00e9 sur l'instabilit\u00e9 intrins\u00e8que des hybridomes producteurs d'anticorps [3] : mutations somatiques dans les s\u00e9quences V, D, et J des g\u00e8nes des r\u00e9gions variables [4], d\u00e9l\u00e9tions affectant les s\u00e9quences d'ADN codant les r\u00e9gions constantes, commutation de classe au cours de laquelle la r\u00e9gion VDJ associ\u00e9e \u00e0 la s\u00e9quence codant la r\u00e9gion constante \u03bc, se recombine avec la s\u00e9quence d'ADN codant la r\u00e9gion constante de l'une des cha\u00eenes \u03b3 [5]. Plus r\u00e9cemment, une approche pour isoler des anticorps recombinants mutants de haute affinit\u00e9 a consist\u00e9 \u00e0 utiliser des lign\u00e9es cellulaires pr\u00e9alablement s\u00e9lectionn\u00e9es pour leur capacit\u00e9 \u00e0 induire un taux \u00e9lev\u00e9 de mutations somatiques dans les domaines variables d'immunoglobuline, coupl\u00e9e \u00e0 un criblage des anticorps mut\u00e9s de haute affinit\u00e9 en utilisant des doses tr\u00e8s faibles d'antig\u00e8ne [6].",
            "cite_spans": [
                {
                    "start": 692,
                    "end": 695,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 781,
                    "end": 784,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1053,
                    "end": 1056,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1447,
                    "end": 1450,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Ing\u00e9nierie cellulaire des anticorps monoclonaux",
            "ref_spans": []
        },
        {
            "text": "Parall\u00e8lement, de nombreux laboratoires ont essay\u00e9 de g\u00e9n\u00e9rer des AcM humains. Des hybridations de lymphocytes humains avec des cellules de my\u00e9lome ont \u00e9t\u00e9 tent\u00e9es avec un succ\u00e8s relatif [7]. L'immortalisation de lymphocytes B humains avec le virus d'Epstein\u2013Barr (EBV) pour g\u00e9n\u00e9rer des lign\u00e9es EBV [8] suivie de la fusion de ces lign\u00e9es avec des cellules de my\u00e9lome ont permis l'obtention de cellules relativement stables productrices d'AcM humains [9], comme des AcM anti-D, anti-toxine t\u00e9tanique (TT) et anti-VIH. Cependant, la palette restreinte d'antig\u00e8nes contre lesquels il est possible d'esp\u00e9rer d'obtenir des anticorps avec ces approches, l'affinit\u00e9 souvent m\u00e9diocre de tels anticorps, la difficult\u00e9 de clonage et l'instabilit\u00e9 des cellules productrices, ont rendu impossible une production \u00e0 une \u00e9chelle industrielle. Les ann\u00e9es 1980 ont alors vu une nouvelle vague de recherche d'ing\u00e9nierie cellulaire : utilisation de partenaires de fusion optimis\u00e9s [10], [11], immunisation in vitro [12], croissance \u00e0 long terme de lymphocytes B humains normaux [13]. D'autres techniques, difficiles \u00e0 mettre en \u0153uvre et de faible efficacit\u00e9, ont \u00e9t\u00e9 \u00e9galement d\u00e9velopp\u00e9es, comme l'injection de lymphocytes humains \u00e0 des souris SCID (Severe Combined ImmunoDeficiency), permettant une expansion in vivo de lymphocytes B humains, qui peuvent \u00eatre stimul\u00e9s ult\u00e9rieurement par injection d'un antig\u00e8ne \u00e0 ces souris. Malgr\u00e9 ces efforts, aucune technique d'ing\u00e9nierie cellulaire fiable, reproductible, facile d'emploi, n'a \u00e9t\u00e9 mise en place dans les ann\u00e9es 1980 et 1990 pour obtenir des anticorps humains. Cependant, l'ing\u00e9nierie cellulaire a peut-\u00eatre r\u00e9cemment retrouv\u00e9 une place de choix dans les strat\u00e9gies d'obtention d'AcM humains. La transformation par l'EBV de lymphocytes B m\u00e9moires CD22+ IgM\u2212, IgD\u2212, IgA\u2212 isol\u00e9s \u00e0 partir de patients infect\u00e9s et victimes du SRAS, suivie de leur stimulation in vitro par des motifs CpG (stimulant la prolif\u00e9ration des lymphocytes B par l'interm\u00e9diaire des r\u00e9cepteurs Toll-like 9, TLR9) a ainsi r\u00e9cemment permis d'isoler un grand nombre de lign\u00e9es EBV productrices d'anticorps anti-coronavirus de forte affinit\u00e9 [14]. Par ailleurs, la possibilit\u00e9 de reconstituer des souris immunod\u00e9ficientes (Rag2\u2212/\u2212 \u03b3c\u2212/\u2212) avec des cellules du syst\u00e8me immunitaire d'origine humaine par injection intra-h\u00e9patique de cellules CD34+ du sang de cordon a ouvert la voie \u00e0 la g\u00e9n\u00e9ration d'anticorps humains apr\u00e8s immunisation de ces souris, comme le sugg\u00e8re l'apparition d'une r\u00e9ponse de type IgG, apr\u00e8s immunisation avec l'anatoxine t\u00e9tanique [15].",
            "cite_spans": [
                {
                    "start": 187,
                    "end": 190,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 299,
                    "end": 302,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 450,
                    "end": 453,
                    "mention": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 962,
                    "end": 966,
                    "mention": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 968,
                    "end": 972,
                    "mention": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 996,
                    "end": 1000,
                    "mention": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1059,
                    "end": 1063,
                    "mention": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 2143,
                    "end": 2147,
                    "mention": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 2554,
                    "end": 2558,
                    "mention": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "section": "Ing\u00e9nierie cellulaire des anticorps monoclonaux",
            "ref_spans": []
        },
        {
            "text": "La manipulation des AcM par g\u00e9nie g\u00e9n\u00e9tique a commenc\u00e9 au d\u00e9but des ann\u00e9es 1980. Cela a permis l'\u00e9mergence sur le march\u00e9 d'anticorps th\u00e9rapeutiques chim\u00e9riques, puis humanis\u00e9s et, enfin, totalement humains (Tableau 1\n). Quatre strat\u00e9gies principales d'ing\u00e9nierie mol\u00e9culaire ont \u00e9t\u00e9 mises en \u0153uvre :",
            "cite_spans": [],
            "section": "Ing\u00e9nierie mol\u00e9culaire des anticorps monoclonaux",
            "ref_spans": [
                {
                    "start": 207,
                    "end": 216,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "\n\u2013la construction d'anticorps chim\u00e9riques [16], qui consiste \u00e0 isoler l'ADN codant pour le domaine VH et le domaine VL d'un AcM murin et \u00e0 le lier \u00e0 l'ADN codant les domaines constants H et L d'une immunoglobuline humaine. Cela permet de produire un anticorps hybride dont la partie constante est humaine : il s'agit en g\u00e9n\u00e9ral de la r\u00e9gion constante des IgG1 humaines (\u03b31) et de la r\u00e9gion constante \u03ba (C\u03ba) humaine. De tels anticorps sont humains \u00e0 75%et moins immunog\u00e8nes que les anticorps de souris, car les \u00e9pitopes immuno-dominants inter-esp\u00e8ces sont principalement localis\u00e9s dans les domaines CH2 et CH3. Dans la plupart des cas, la sp\u00e9cificit\u00e9 et l'affinit\u00e9 des anticorps chim\u00e9riques restent identiques \u00e0 celles des anticorps murins parentaux. De l\u00e9g\u00e8res modifications de la sp\u00e9cificit\u00e9 fine ont cependant \u00e9t\u00e9 parfois observ\u00e9es, sugg\u00e9rant une influence des r\u00e9gions constantes sur la topologie des domaines variables [17]. Cinq anticorps chim\u00e9riques sont actuellement sur le march\u00e9 (Tableau 1) ;\u2013la construction d'anticorps humanis\u00e9s par greffe de r\u00e9gions hypervariables d'AcM de souris sur des r\u00e9gions charpentes (Frameworks, FR) VH et VL humaines (Complementarity Determining Regions \u2013 CDRs \u2013 grafting) [18]. La substitution des r\u00e9gions hypervariables d'AcM murins aux r\u00e9gions hypervariables de domaines VH et VL humains permet d'obtenir des anticorps humanis\u00e9s, a priori peu immunog\u00e8nes chez l'homme, car seules les r\u00e9gions hypervariables ont une origine murine. La difficult\u00e9 de cette approche r\u00e9side dans le choix des domaines VH et VL humains sur lesquels ces r\u00e9gions hypervariables vont s'ins\u00e9rer. En effet, certains acides amin\u00e9s situ\u00e9s en dehors des r\u00e9gions hypervariables jouent un r\u00f4le essentiel dans la conformation de l'anticorps. Certains changements de r\u00e9sidus de la r\u00e9gion charpente peuvent ainsi modifier consid\u00e9rablement l'affinit\u00e9 de l'anticorps humanis\u00e9 obtenu. Le choix des domaines VH et VL humains sur lesquels s'effectue la substitution des CDRs est d\u00e9termin\u00e9 par des exp\u00e9riences de mod\u00e9lisation et de comparaison du repliement de diff\u00e9rents domaines VH et VL humains germinaux avec ceux des domaines VH et VL de l'anticorps parental murin. La d\u00e9finition de la structure tridimensionnelle de la r\u00e9gion Fab de l'anticorps murin parental par cristallographie et diffraction aux rayons X donne des informations majeures pour orienter ce choix. Une m\u00e9thode alternative a \u00e9t\u00e9 fond\u00e9e sur l'analyse syst\u00e9matique de la distribution des acides amin\u00e9s expos\u00e9s aux solvants dans les domaines variables murins et humains. L'usage de tel ou tel acide amin\u00e9 \u00e0 ces positions expos\u00e9es signe en effet un profil particulier, sp\u00e9cifique de chaque anticorps (surface residues pattern). On peut alors, par mutagen\u00e8se dirig\u00e9e, convertir un profil murin en un profil humain \u00e0 l'aide d'un nombre restreint de substitutions d'acides amin\u00e9s, sans modifier les capacit\u00e9s de liaison \u00e0 l'antig\u00e8ne. Cette technique (variable domain resurfacing) a \u00e9t\u00e9 utilis\u00e9e pour humaniser diff\u00e9rents anticorps monoclonaux [19]. Sept anticorps humanis\u00e9s sont actuellement sur le march\u00e9 (Tableau 1) ;\u2013la construction de banques combinatoires de r\u00e9gions VH et VL humaines exprim\u00e9es \u00e0 la surface de phages (phage display) [20]. Cette approche a \u00e9t\u00e9 rendue possible par la ma\u00eetrise des techniques d'expression de peptides \u00e0 la surface des phages filamenteux [21] et de g\u00e9n\u00e9ration et d'expression chez E. coli de fragments recombinants scFv (single-chain Fv) liant une r\u00e9gion VH et une r\u00e9gion VL ou de fragments recombinants F(ab), constitu\u00e9s de la cha\u00eene l\u00e9g\u00e8re associ\u00e9e au segment peptidique VH-CH1 [22], [23]. Pour cr\u00e9er un r\u00e9pertoire d'anticorps avec le syst\u00e8me du \u00ab phage display \u00bb, on peut utiliser indiff\u00e9remment des g\u00e8nes V r\u00e9arrang\u00e9s in vivo provenant d'une population de lymphocytes B ou des g\u00e8nes V \u00ab synth\u00e9tiques \u00bb construits in vitro [24], [25]. Les ADNc codant les domaines variables sont synth\u00e9tis\u00e9s par RT-PCR, format\u00e9s de fa\u00e7on \u00e0 coder des fragments d'anticorps de type scFv ou Fab et clon\u00e9s alors dans des phages ou des phag\u00e9mides. Ce clonage permet d'ins\u00e9rer les ADNc en amont d'une s\u00e9quence codant une prot\u00e9ine de l'enveloppe du phage (g3p ou, moins fr\u00e9quemment, g8p quand il s'agit de phag\u00e9mides). Des banques de tr\u00e8s grandes tailles ont \u00e9t\u00e9 obtenues par utilisation de syst\u00e8me de recombinaison de type Cre/Lox ou Int/Att\n[26], mais leur construction reste complexe et leur stabilit\u00e9 difficile \u00e0 contr\u00f4ler. La technique du phage display permet \u00e9galement de g\u00e9n\u00e9rer des anticorps de haute affinit\u00e9 par mutation dirig\u00e9e ou par mutation al\u00e9atoire, imitant ainsi le ph\u00e9nom\u00e8ne d'hypermutation observ\u00e9 lors de la maturation des r\u00e9ponses anticorps in vivo. De tr\u00e8s nombreuses adaptations de la technique du phage display, portant sur la construction des banques et sur les m\u00e9thodes de s\u00e9lection des anticorps, ont \u00e9t\u00e9 d\u00e9crites au cours des quinze derni\u00e8res ann\u00e9es [27]. Une autre approche de s\u00e9lection d'anticorps est le ribosome display, fond\u00e9 sur la production d'ARNm \u00e0 partir de banques de scFv, traduits in vitro dans un syst\u00e8me acellulaire [28]. Un complexe ribosome\u2013polypeptide (cha\u00eene naissante du scFv) est s\u00e9lectionn\u00e9 gr\u00e2ce \u00e0 l'exclusion d'un codon non-sens et l'ARN codant le scFv est isol\u00e9. Enfin, une technique prometteuse, fond\u00e9e sur l'expression de fragments scFv \u00e0 la surface de levures (Saccharomyces cerevisiae) en fusion avec la mol\u00e9cule Aga2p [29] a r\u00e9cemment permis le criblage de banques d'anticorps par immunofluorescence : les levures marqu\u00e9es sont ais\u00e9ment tri\u00e9es et isol\u00e9es, et l'ADNc codant les fragments d'anticorps isol\u00e9 [30]. Dans toutes ces approches, les fragments d'anticorps isol\u00e9s \u00e0 partir des banques sont ensuite reformat\u00e9s en IgG humaine enti\u00e8re, comme dans le cas des anticorps chim\u00e9riques et humanis\u00e9s. Il a \u00e9t\u00e9 ainsi possible d'isoler \u00e0 partir de ces banques des fragments d'anticorps liant diff\u00e9rents antig\u00e8nes et auto-antig\u00e8nes, notamment le TNF\u03b1 (Tableau 1). La plupart des AcM recombinants, qu'ils soient chim\u00e9riques, humanis\u00e9s, ou d\u00e9riv\u00e9s de banques de fragments d'anticorps, contiennent une r\u00e9gion Fc d\u00e9riv\u00e9e d'une IgG1 humaine. Cette sous-classe poss\u00e8de en effet des caract\u00e9ristiques (liaison aux RFc\u03b3, fixation au C1q, demi-vie s\u00e9rique) et des propri\u00e9t\u00e9s fonctionnelles (ADCC, endocytose, phagocytose, activation de la voie classique du compl\u00e9ment) int\u00e9ressantes pour l'immunoth\u00e9rapie. Cependant, il peut \u00eatre pr\u00e9f\u00e9rable, dans certaines situations th\u00e9rapeutiques ou en fonction du type de traitement, d'utiliser des r\u00e9gions Fc d\u00e9riv\u00e9es d'IgG2 ou d'IgG4, si l'on veut \u00e9viter une activation des m\u00e9canismes effecteurs et diminuer les fixations non sp\u00e9cifiques sur des tissus normaux ;\u2013l'obtention de souris transg\u00e9niques contenant une grande partie des g\u00e8nes codant les cha\u00eenes lourdes et l\u00e9g\u00e8res humaines [31], [32], [33]. Cette approche consiste \u00e0 remplacer les loci des g\u00e8nes d'immunoglobulines (Ig) de souris par les loci \u00e9quivalents humains en utilisant des fragments d'ADN g\u00e9nomique humain, contenus dans des Yeast Artificial Chromosomses (YACs) [31], [32]. Des souris dont une grande partie des loci IgH et Ig\u03ba avait \u00e9t\u00e9 inactiv\u00e9e (moIgK.O.) et des souris transg\u00e9niques contenant une partie des loci d'Ig humaines (huIgTg) ont \u00e9t\u00e9 g\u00e9n\u00e9r\u00e9es et crois\u00e9es. Il a \u00e9t\u00e9 alors montr\u00e9 que les souris issues de ce croisement [huIgTg \u00d7 moIgK.O.] produisent des anticorps humains de type IgM, ou IgG lors de r\u00e9ponses secondaires, d\u00e9montrant que les fragments introduits permettent l'expression des cha\u00eenes lourdes et l\u00e9g\u00e8res humaines, ainsi que la commutation de classe. De plus, l'analyse des AcM obtenus a montr\u00e9 que des mutations somatiques affectaient les r\u00e9gions variables lors de la r\u00e9ponse secondaire, indiquant l'existence d'une maturation de la r\u00e9ponse anticorps. Ces souris permettent ainsi de g\u00e9n\u00e9rer des AcM humains de haute affinit\u00e9 contre n'importe quel antig\u00e8ne [31], [32]. Une approche fond\u00e9e sur l'introduction de fragments chromosomiques humains entiers (technologie \u00ab trans-chromosomique \u00bb, Tc) a \u00e9t\u00e9 \u00e9galement d\u00e9velopp\u00e9e [33]. Des souris invalid\u00e9es en ce qui concerne leurs loci IgH et Ig\u03ba ont \u00e9t\u00e9 rendues double-trans-chromosomiques par introduction de fragments d\u00e9riv\u00e9s des chromosomes humains 14 et 22 contenant respectivement le locus IGH et le locus IGK. Cela a permis de g\u00e9n\u00e9rer des souris dont un certain nombre de cellules somatiques contiennent 100%des g\u00e8nes codant les cha\u00eenes lourdes et les cha\u00eenes l\u00e9g\u00e8res \u03ba humaines. Ces souris produisent des quantit\u00e9s \u00e9lev\u00e9es d'IgG humaines en r\u00e9ponse \u00e0 diff\u00e9rents immunog\u00e8nes. Des anticorps monoclonaux humains peuvent \u00eatre obtenus alors par la technique classique d'obtention d'hybridomes B.\n",
            "cite_spans": [
                {
                    "start": 42,
                    "end": 46,
                    "mention": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 922,
                    "end": 926,
                    "mention": "[17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 1210,
                    "end": 1214,
                    "mention": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 3007,
                    "end": 3011,
                    "mention": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 3203,
                    "end": 3207,
                    "mention": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 3338,
                    "end": 3342,
                    "mention": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 3580,
                    "end": 3584,
                    "mention": "[22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 3586,
                    "end": 3590,
                    "mention": "[23]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 3826,
                    "end": 3830,
                    "mention": "[24]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 3832,
                    "end": 3836,
                    "mention": "[25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 4322,
                    "end": 4326,
                    "mention": "[26]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 4857,
                    "end": 4861,
                    "mention": "[27]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 5038,
                    "end": 5042,
                    "mention": "[28]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 5355,
                    "end": 5359,
                    "mention": "[29]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 5542,
                    "end": 5546,
                    "mention": "[30]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 6744,
                    "end": 6748,
                    "mention": "[31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 6750,
                    "end": 6754,
                    "mention": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 6756,
                    "end": 6760,
                    "mention": "[33]",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 6990,
                    "end": 6994,
                    "mention": "[31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 6996,
                    "end": 7000,
                    "mention": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 7809,
                    "end": 7813,
                    "mention": "[31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 7815,
                    "end": 7819,
                    "mention": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 7973,
                    "end": 7977,
                    "mention": "[33]",
                    "ref_id": "BIBREF32"
                }
            ],
            "section": "Ing\u00e9nierie mol\u00e9culaire des anticorps monoclonaux",
            "ref_spans": [
                {
                    "start": 988,
                    "end": 997,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 3071,
                    "end": 3080,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 5883,
                    "end": 5892,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "En moins d'une d\u00e9cade, le nombre d'AcM ayant re\u00e7u une autorisation de mise sur le march\u00e9 ou d'utilisation pour le traitement de pathologies aussi diverses que les lympho-prolif\u00e9rations, les tumeurs solides, les maladies inflammatoires, l'asthme allergique, ou pour la pr\u00e9vention du rejet de greffe, a connu une augmentation spectaculaire (Tableau 1). Le nombre impressionnant d'AcM actuellement \u00e9valu\u00e9s dans des essais de phases II et III (plus de 150) pr\u00e9sage une acc\u00e9l\u00e9ration de cet accroissement dans les prochaines ann\u00e9es. De nombreux essais d'immunoth\u00e9rapie sont actuellement effectu\u00e9s avec des AcM de souris, chim\u00e9ris\u00e9s, humanis\u00e9s, ou humains. Il existe plusieurs approches dans ces essais. La plus simple consiste \u00e0 injecter \u00e0 des malades des AcM dirig\u00e9s contre diff\u00e9rents antig\u00e8nes associ\u00e9s aux tumeurs, contre des r\u00e9cepteurs de facteurs de croissance, des cytokines, des facteurs solubles pro-angiog\u00e9niques, ou des mol\u00e9cules de surface induisant une apoptose cellulaire, une anergie ou une activation cellulaire selon les cas. Afin de rendre les anticorps anti-antig\u00e8nes associ\u00e9s aux tumeurs plus efficaces, des techniques de couplage des anticorps \u00e0 des toxines (notamment la ricine et la toxine de Pseudomonas), ou \u00e0 des drogues utilis\u00e9es pour la chimioth\u00e9rapie, comme le m\u00e9thotrexate, ont \u00e9t\u00e9 d\u00e9velopp\u00e9es. Une autre approche d'utilisation d'AcM par th\u00e9rapie g\u00e9nique a \u00e9t\u00e9 \u00e9galement explor\u00e9e depuis quelques ann\u00e9es : des fragments d'anticorps (anti-virus, anti-oncog\u00e8nes, anti-enzymes) ont \u00e9t\u00e9 exprim\u00e9s dans des cellules tumorales, dans des cellules infect\u00e9es par des virus (y compris des cellules de plantes) pour bloquer ou moduler les fonctions de prot\u00e9ines intracellulaires (intrabodies) [34], [35].",
            "cite_spans": [
                {
                    "start": 1703,
                    "end": 1707,
                    "mention": "[34]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 1709,
                    "end": 1713,
                    "mention": "[35]",
                    "ref_id": "BIBREF34"
                }
            ],
            "section": "Optimisation des propri\u00e9t\u00e9s effectrices des anticorps monoclonaux",
            "ref_spans": [
                {
                    "start": 339,
                    "end": 348,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Afin de renforcer les propri\u00e9t\u00e9s effectrices des AcM, diff\u00e9rentes techniques ont consist\u00e9 \u00e0 les transformer, par voie chimique ou par g\u00e9nie g\u00e9n\u00e9tique, en anticorps bisp\u00e9cifiques, ce qui permet un pontage entre des cellules tueuses de l'h\u00f4te et les cellules tumorales et provoque une potentialisation de la cytotoxicit\u00e9 anti-tumorale [36]. Les recherches ont \u00e9galement port\u00e9 sur l'optimisation des propri\u00e9t\u00e9s effectrices des r\u00e9gions Fc par mutation ponctuelle et par modification du profil de glycosylation. L'une des strat\u00e9gies d\u00e9velopp\u00e9es pour obtenir des AcM cytotoxiques optimis\u00e9s consiste \u00e0 les modifier de fa\u00e7on \u00e0 ce qu'ils recrutent plus efficacement le C1q, notamment en diminuant leur Koff\n[37]. Une autre approche consiste \u00e0 cribler des anticorps dont la s\u00e9quence a \u00e9t\u00e9 mut\u00e9e par rapport \u00e0 l'anticorps d'origine, criblage reposant sur l'analyse des interactions de ces anticorps avec diff\u00e9rents types de RFc\u03b3 et/ou sur leur capacit\u00e9 \u00e0 induire efficacement des fonctions effectrices [38]. Selon la pathologie cibl\u00e9e, la strat\u00e9gie peut consister \u00e0 augmenter ou \u00e0 diminuer les interactions IgG/RFc\u03b3. Les AcM cytotoxiques poss\u00e9dant une capacit\u00e9 d'engagement des RFc\u03b3 activateurs accrue (RFc\u03b3IIA, RFc\u03b3IIIA) et une interaction r\u00e9duite avec les RFc\u03b3 inhibiteurs (RFc\u03b3IIB1, RFc\u03b3IIB2) sont susceptibles d'avoir une activit\u00e9 anti-virale ou anti-tumorale optimis\u00e9e. En revanche, des AcM qui engagent pr\u00e9f\u00e9rentiellement les RFc\u03b3 inhibiteurs sans recruter les RFc\u03b3 activateurs sont potentiellement utilisables dans le traitement de pathologies auto-immunes. Enfin, l'utilisation d'AcM incapables de recruter les RFc\u03b3 ou interagissant faiblement avec ceux-ci peut \u00eatre d'un grand int\u00e9r\u00eat pour \u00e9viter les effets secondaires d'une immunoth\u00e9rapie, dus \u00e0 la lib\u00e9ration de cytokines \u00e0 la suite du recrutement de cellules effectrices immunes (cytokine syndrome release). L'ing\u00e9nierie du profil de glycosylation de la r\u00e9gion Fc des IgG1 humaines (l'isotype utilis\u00e9 dans la tr\u00e8s grande majorit\u00e9 des AcM commercialis\u00e9s) est une autre strat\u00e9gie utilis\u00e9e pour optimiser les fonctions effectrices des AcM. En effet, non seulement la glycosylation per se joue un r\u00f4le dans la structure globale de la r\u00e9gion Fc des IgG et est n\u00e9cessaire \u00e0 la liaison aux RFc\u03b3, mais la composition pr\u00e9cise de l'oligosaccharide fix\u00e9 \u00e0 l'asparagine 297 a un impact sur les interactions IgG/RFc\u03b3. D'une part, la pr\u00e9sence de r\u00e9sidus N-ac\u00e9tyl-glucosamine (GlcNA) interm\u00e9diaires permet aux IgG1 humaines de se lier plus fortement aux RFc\u03b3III (pr\u00e9sents notamment sur les cellules NK) et \u00e0 induire une ADCC accrue [39]. D'autre part, une absence de fucose [40] ou un faible taux de ce sucre [41] permet \u00e9galement une fixation accrue aux RFc\u03b3III et une meilleure ADCC. Un faible taux de fucose a \u00e9galement un impact sur l'engagement du RFc\u03b3IIB (r\u00e9cepteur inhibiteur), qui est am\u00e9lior\u00e9 [41]. Cette capacit\u00e9 des IgG peu fucosyl\u00e9es \u00e0 lier plus fortement le RFc\u03b3III et, dans une moindre mesure, le RFc\u03b3IIB, a r\u00e9cemment permis de s\u00e9lectionner un AcM humain anti-D, dans le cadre de la pr\u00e9vention de l'allo-immunisation f\u0153to-maternelle [41], anticorps qui a montr\u00e9 une excellente capacit\u00e9 de clairance dans un essai de phase I chez l'homme (Beliard et al., en pr\u00e9paration).",
            "cite_spans": [
                {
                    "start": 333,
                    "end": 337,
                    "mention": "[36]",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 698,
                    "end": 702,
                    "mention": "[37]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 991,
                    "end": 995,
                    "mention": "[38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 2569,
                    "end": 2573,
                    "mention": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 2611,
                    "end": 2615,
                    "mention": "[40]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 2646,
                    "end": 2650,
                    "mention": "[41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 2839,
                    "end": 2843,
                    "mention": "[41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 3084,
                    "end": 3088,
                    "mention": "[41]",
                    "ref_id": "BIBREF40"
                }
            ],
            "section": "Optimisation des propri\u00e9t\u00e9s effectrices des anticorps monoclonaux",
            "ref_spans": []
        },
        {
            "text": "L'optimisation des propri\u00e9t\u00e9s effectrices des AcM, outre son int\u00e9r\u00eat pour atteindre une meilleure efficacit\u00e9 clinique, a \u00e9galement un grand int\u00e9r\u00eat potentiel d'un point de vue industriel et \u00e9conomique : elle pourrait permettre de diminuer les doses requises pour les traitements et donc le co\u00fbt de ces derniers (qui pour certains AcM atteignent actuellement des montants situ\u00e9s entre 15 000 et 20 000 \u20ac par an). Plusieurs technologies peuvent th\u00e9oriquement s'utiliser pour la production des AcM en fonction des caract\u00e9ristiques d\u00e9sir\u00e9es du produit final et des quantit\u00e9s n\u00e9cessaires \u00e0 sa commercialisation \u00e0 une \u00e9chelle r\u00e9gionale ou mondiale [42] (Fig. 1\n).",
            "cite_spans": [
                {
                    "start": 642,
                    "end": 646,
                    "mention": "[42]",
                    "ref_id": "BIBREF41"
                }
            ],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": [
                {
                    "start": 648,
                    "end": 654,
                    "mention": "Fig. 1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Il existe deux grands types possibles de proc\u00e9d\u00e9s pour produire les quantit\u00e9s n\u00e9cessaires d'AcM pour les \u00e9tudes cliniques et leur commercialisation : des proc\u00e9d\u00e9s fond\u00e9s sur la culture cellulaire et des proc\u00e9d\u00e9s faisant appel \u00e0 la transgen\u00e8se. En fait, les AcM actuellement sur le march\u00e9 ou \u00e9valu\u00e9s dans des essais cliniques sont produits in vitro dans des cellules eucaryotes de mammif\u00e8res (principalement CHO et NS0) [42], [43]. Les diff\u00e9rentes lign\u00e9es cellulaires utilis\u00e9es (qui incluent \u00e9galement YB2/0 et PERC-6) sont cultiv\u00e9es en suspension dans des milieux de culture sans prot\u00e9ine, en particulier sans prot\u00e9ine d'origine animale. Les proc\u00e9d\u00e9s de fabrication sont mis au point dans des unit\u00e9s pilotes (Fig. 2\n), puis transf\u00e9r\u00e9s dans des unit\u00e9s de fabrication aux normes des \u00ab bonnes pratiques de fabrication \u00bb (BPF). Pour satisfaire les besoins th\u00e9rapeutiques, qui sont de plus en plus importants, les industriels sont amen\u00e9s \u00e0 produire des quantit\u00e9s de l'ordre de dizaines de kilogrammes d'anticorps. \u00c0 cette fin, des unit\u00e9s industrielles de bior\u00e9acteurs de 10 000 litres, voire plus, ont \u00e9t\u00e9 construites, notamment aux \u00c9tats-Unis et au Royaume-Uni. Tous les anticorps commercialis\u00e9s \u00e0 ce jour sont produits selon ces proc\u00e9d\u00e9s de culture de cellules en suspension dans des bior\u00e9acteurs. En effet, en ce qui concerne la production d'AcM sous forme d'IgG enti\u00e8re, la production dans des bact\u00e9ries n'est toujours pas ma\u00eetris\u00e9e : d'une part, la production de quantit\u00e9s \u00e9lev\u00e9es de mol\u00e9cules recombinantes h\u00e9t\u00e9rologues reste toxique pour les bact\u00e9ries et, d'autre part, cette expression ne permet pas l'obtention de mol\u00e9cules ayant des propri\u00e9t\u00e9s fonctionnelles correctes du fait de l'absence de N-glycosylation. La production dans des bact\u00e9ries, peu on\u00e9reuse, est cependant bien adapt\u00e9e \u00e0 la production de fragments d'anticorps comme les scFv et les Fab.",
            "cite_spans": [
                {
                    "start": 419,
                    "end": 423,
                    "mention": "[42]",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 425,
                    "end": 429,
                    "mention": "[43]",
                    "ref_id": "BIBREF42"
                }
            ],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": [
                {
                    "start": 709,
                    "end": 715,
                    "mention": "Fig. 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "Un effort particulier est actuellement soutenu pour la ma\u00eetrise d'AcM dans la levure. Plusieurs \u00e9quipes ont fabriqu\u00e9 des levures recombinantes transfect\u00e9es avec diff\u00e9rentes glycosyltransf\u00e9rases afin d'obtenir des anticorps pr\u00e9sentant une glycosylation ad\u00e9quate et contr\u00f4l\u00e9e. Ce syst\u00e8me de production, s'il arrivait \u00e0 \u00eatre ma\u00eetris\u00e9, permettrait certainement d'abaisser de fa\u00e7on significative le co\u00fbt de production des AcM.",
            "cite_spans": [],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": []
        },
        {
            "text": "Plusieurs esp\u00e8ces animales ont \u00e9t\u00e9 utilis\u00e9es pour la production d'AcM : lapins, brebis, ch\u00e8vres, vaches. Les anticorps ont en g\u00e9n\u00e9ral \u00e9t\u00e9 produits dans le lait des animaux en utilisant des vecteurs d'expression contenant des promoteurs sp\u00e9cifiques des cellules de la glande mammaire. Cette production est cependant encore rest\u00e9e au stade de la d\u00e9monstration de la faisabilit\u00e9. Cette approche permet de produire de grandes quantit\u00e9s d'anticorps \u00e0 des co\u00fbts tr\u00e8s comp\u00e9titifs par rapport aux proc\u00e9d\u00e9s in vitro. Toutefois, l'utilisation d'animaux transg\u00e9niques, outre les angoisses \u00ab soci\u00e9tales \u00bb de s\u00e9curit\u00e9 biologique inh\u00e9rentes \u00e0 cette approche, pr\u00e9sente certaines limites comme le d\u00e9lai d'obtention et de s\u00e9lection des animaux transg\u00e9niques et la purification de la prot\u00e9ine d'int\u00e9r\u00eat \u00e0 partir du lait. De plus, ces approches n\u00e9cessitent de ma\u00eetriser les diff\u00e9rentes modifications post-traductionnelles des IgG produites, propres \u00e0 chaque esp\u00e8ce.",
            "cite_spans": [],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": []
        },
        {
            "text": "Enfin, plusieurs plantes ont \u00e9t\u00e9 utilis\u00e9es pour la pr\u00e9paration d'AcM (plantibodies) : colza, tabac, riz, bl\u00e9, ma\u00efs. Cette approche est sans doute une des approches permettant \u00e0 terme un abaissement significatif des co\u00fbts de production des AcM. Cependant, une des limites majeures \u00e0 la production de prot\u00e9ines dans les plantes est li\u00e9e \u00e0 la pr\u00e9sence de motifs oligosaccharidiques particuliers comme le xylose, dont la pr\u00e9sence pose d'importants probl\u00e8mes de tol\u00e9rance et d'immunog\u00e9nicit\u00e9. Certaines glycosyltransf\u00e9rases de plantes ont d\u00e9j\u00e0 \u00e9t\u00e9 modifi\u00e9es par invalidation g\u00e9nique et transgen\u00e8se pour obtenir des anticorps pr\u00e9sentant des glycosylations proches de celles des Ig humaines. Comme dans le cas des animaux transg\u00e9niques, cette approche reste en devenir. Par ailleurs, des essais de production d'AcM dans des cellules v\u00e9g\u00e9tales cultiv\u00e9es in vitro ont aussi \u00e9t\u00e9 r\u00e9alis\u00e9s avec succ\u00e8s. Cette approche innovante, \u00e9galement moins on\u00e9reuse que l'utilisation de cellules de mammif\u00e8res, permettrait d'\u00e9viter la culture des plantes transg\u00e9niques en champs et de r\u00e9aliser des productions en milieu confin\u00e9 (bior\u00e9acteurs).",
            "cite_spans": [],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": []
        },
        {
            "text": "La purification d'AcM \u00e0 partir de surnageants de culture est relativement facile, d'autant plus que les milieux de culture utilis\u00e9s sont d\u00e9pourvus de prot\u00e9ines exog\u00e8nes [42], [43]. La premi\u00e8re \u00e9tape consiste \u00e0 clarifier et \u00e0 concentrer les surnageants de culture. Une chromatographie d'affinit\u00e9 utilisant de la prot\u00e9ine A est ensuite utilis\u00e9e, les anticorps \u00e9tant des IgG dans leur immense majorit\u00e9. Au moins une \u00e9tape de chromatographie \u00e9changeuse d'ions est alors ajout\u00e9e au proc\u00e9d\u00e9, ce qui permet d'\u00e9liminer l'ADN r\u00e9siduel et les prot\u00e9ines de la lign\u00e9e productrice contaminantes (HCPs, pour Host Cell Proteins). Les protocoles classiques permettent ainsi d'obtenir des anticorps ayant un taux de puret\u00e9 sup\u00e9rieur \u00e0 99,9%. Un traitement solvant\u2013d\u00e9tergent permettant une inactivation de virus envelopp\u00e9s potentiellement pr\u00e9sents ainsi qu'une \u00e9tape de nanofiltration (15 nm au LFB), permettant d'\u00e9liminer les particules virales, sont ajout\u00e9s au proc\u00e9d\u00e9 de purification pour assurer une s\u00e9curit\u00e9 biologique maximale. Les diff\u00e9rentes \u00e9tapes du proc\u00e9d\u00e9 sont test\u00e9es et valid\u00e9es pour leur capacit\u00e9 \u00e0 \u00e9liminer toute trace de contaminants (ADN, virus contaminants potentiellement produits par les lign\u00e9es cellulaires productrices). Une fois purifi\u00e9s, les AcM sont g\u00e9n\u00e9ralement conditionn\u00e9s sous forme liquide, pr\u00eats \u00e0 l'emploi, \u00e0 des concentrations de l'ordre du mg/ml, voire \u00e0 des concentrations plus \u00e9lev\u00e9es.",
            "cite_spans": [
                {
                    "start": 169,
                    "end": 173,
                    "mention": "[42]",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 175,
                    "end": 179,
                    "mention": "[43]",
                    "ref_id": "BIBREF42"
                }
            ],
            "section": "Production des anticorps monoclonaux \u00e0 l'\u00e9chelle industrielle",
            "ref_spans": []
        },
        {
            "text": "Les ann\u00e9es \u00e0 venir vont tr\u00e8s certainement voir le nombre d'AcM mis sur le march\u00e9 s'accro\u00eetre sensiblement, dans des indications de plus en plus vari\u00e9es et pour lesquelles l'arsenal th\u00e9rapeutique actuel est restreint, voire inexistant. La premi\u00e8re g\u00e9n\u00e9ration d'AcM apparue \u00e0 la fin des ann\u00e9es 1980 et au milieu des ann\u00e9es 1990 va c\u00e9der la place \u00e0 de nouvelles mol\u00e9cules, dont l'efficacit\u00e9, l'immunog\u00e9nicit\u00e9 et les propri\u00e9t\u00e9s pharmacocin\u00e9tiques seront mieux contr\u00f4l\u00e9es et optimis\u00e9es. Ces moveaux anticorps, utilis\u00e9s \u00e9ventuellement en synergie avec d'autres (une approche \u00ab oligoclonale \u00bb se dessine d\u00e9j\u00e0 pour certaines indications, comme les traitements anti-tumoraux et la neutralisation de toxines) ou d'autres biomol\u00e9cules ou compos\u00e9s chimiques, chez des patients \u00e0 des stades plus pr\u00e9coces de leur maladie, notamment en oncologie, sont susceptibles de constituer une classe de m\u00e9dicaments exceptionnellement efficaces. L'arriv\u00e9e de ces nouveaux anticorps, dirig\u00e9s contre les m\u00eames cibles que les AcM de premi\u00e8re g\u00e9n\u00e9ration, et pour lesquels de nombreux brevets vont expirer dans les prochaines ann\u00e9es, pose d\u00e9sormais la question de la d\u00e9finition de ce qu'est un anticorps \u00ab g\u00e9n\u00e9rique \u00bb biosimilaires. Pour des produits biotechnologiques comme les AcM, le processus de fabrication d\u00e9finit le produit final. En effet, les conditions de production des AcM peuvent avoir un impact direct sur leurs caract\u00e9ristiques structurales (modifications post-traductionnelles et composition en oligosaccharides en particulier) et sur leurs propri\u00e9t\u00e9s fonctionnelles. C'est pourquoi les agences r\u00e9glementaires ont propos\u00e9 le terme de m\u00e9dicaments biosimilaires. La qualification de m\u00e9dicaments g\u00e9n\u00e9riques est r\u00e9serv\u00e9e aux produits issus d'une synth\u00e8se chimique. Une nouvelle proc\u00e9dure d'autorisation de mise sur le march\u00e9, diff\u00e9rente de celle appliqu\u00e9e aux m\u00e9dicaments g\u00e9n\u00e9riques, est en cours de pr\u00e9paration au niveau europ\u00e9en pour les m\u00e9dicaments biosimilaires.",
            "cite_spans": [],
            "section": "Conclusion : vers des anticorps monoclonaux biosimilaires",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Tableau 1: Anticorps monoclonaux \u00e0 usage th\u00e9rapeutique\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Fig. 1: Le proc\u00e9d\u00e9 de fabrication est d\u00e9fini en fonction de param\u00e8tres dont les deux plus importants sont : (1) les caract\u00e9ristiques structurales de la mol\u00e9cule (taille, complexit\u00e9, importance des modifications post-traductionnelles) ; (2) les quantit\u00e9s \u00e0 produire en vue des des applications th\u00e9rapeutiques.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 2: Bior\u00e9acteur de 250 l pour la mise au point des proc\u00e9d\u00e9s de fabrication au Laboratoire fran\u00e7ais du fractionnement et des biotechnologies (LFB) (\u00e9chelle pilote non BPF).",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Continuous cultures of fused cells secreting antibody of predefined specificity",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "K\u00f6hler",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Milstein",
                    "suffix": ""
                }
            ],
            "year": 1975,
            "venue": "Nature",
            "volume": "256",
            "issn": "",
            "pages": "495-497",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Molecular basis of Fc receptor function",
            "authors": [
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Hulett",
                    "suffix": ""
                },
                {
                    "first": "P.M.",
                    "middle": [],
                    "last": "Hogarth",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Adv. Immunol.",
            "volume": "57",
            "issn": "",
            "pages": "1-127",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "The production of more useful monoclonal antibodies. II. The use of somatic-cell genetic and recombinant DNA technology to tailor-make monoclonal antibodies",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Aguila",
                    "suffix": ""
                },
                {
                    "first": "R.R.",
                    "middle": [],
                    "last": "Pollock",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Spira",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Scharff",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "Immunol. Today",
            "volume": "7",
            "issn": "",
            "pages": "380-383",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Monoclonal antibodies reveal the structural basis of antibody diversity",
            "authors": [
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Desaymard",
                    "suffix": ""
                },
                {
                    "first": "A.M.",
                    "middle": [],
                    "last": "Giusti",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Haseltine",
                    "suffix": ""
                },
                {
                    "first": "R.R.",
                    "middle": [],
                    "last": "Pollock",
                    "suffix": ""
                },
                {
                    "first": "D.E.",
                    "middle": [],
                    "last": "Yelton",
                    "suffix": ""
                },
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Zack",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Scharff",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Science",
            "volume": "222",
            "issn": "",
            "pages": "721-726",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "The identification of monoclonal class switch variants by Sib Selection and an ELISA assay",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Spira",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Bargellesi",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Scharff",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "J. Immunol. Methods",
            "volume": "74",
            "issn": "",
            "pages": "307-315",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Generation and iterative affinity maturation of antibodies in using hypermutating B-cell lines",
            "authors": [
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Cumbers",
                    "suffix": ""
                },
                {
                    "first": "G.T.",
                    "middle": [],
                    "last": "Williams",
                    "suffix": ""
                },
                {
                    "first": "S.L.",
                    "middle": [],
                    "last": "Davies",
                    "suffix": ""
                },
                {
                    "first": "R.L.",
                    "middle": [],
                    "last": "Grenfell",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Takeda",
                    "suffix": ""
                },
                {
                    "first": "F.D.",
                    "middle": [],
                    "last": "Batista",
                    "suffix": ""
                },
                {
                    "first": "J.E.",
                    "middle": [],
                    "last": "Sale",
                    "suffix": ""
                },
                {
                    "first": "M.S.",
                    "middle": [],
                    "last": "Neuberger",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Nat. Biotechnol.",
            "volume": "20",
            "issn": "",
            "pages": "1129-1134",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Human\u2013human hybridomas producing monoclonal antibodies of predefined antigenic specificity",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Olsson",
                    "suffix": ""
                },
                {
                    "first": "H.S.",
                    "middle": [],
                    "last": "Kaplan",
                    "suffix": ""
                }
            ],
            "year": 1980,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "77",
            "issn": "",
            "pages": "5429-5431",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "EB virus induced B lymphocyte cell lines producing specific antibodies",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Steinitz",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Klein",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Koskimies",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Makela",
                    "suffix": ""
                }
            ],
            "year": 1977,
            "venue": "Nature",
            "volume": "269",
            "issn": "",
            "pages": "420-422",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Human hybridomas constructed with antigen-specific Epstein\u2013Barr virus-transformed cell lines",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Kozbor",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Lagarde",
                    "suffix": ""
                },
                {
                    "first": "J.-C.",
                    "middle": [],
                    "last": "Roder",
                    "suffix": ""
                }
            ],
            "year": 1982,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "79",
            "issn": "",
            "pages": "6651-6655",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Mouse \u00d7 human hetero-hybridomas as fusion partners with human B cell tumors",
            "authors": [
                {
                    "first": "W.L.",
                    "middle": [],
                    "last": "Carroll",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Thielemans",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Dilley",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Levy",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "J. Immunol. Methods",
            "volume": "89",
            "issn": "",
            "pages": "61-72",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "A human myeloma cell line suitable for the generation of human monoclonal antibodies",
            "authors": [
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Karpas",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Dremucheva",
                    "suffix": ""
                },
                {
                    "first": "B.H.",
                    "middle": [],
                    "last": "Czepulkowski",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "98",
            "issn": "",
            "pages": "1799-1804",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "In vitro immunization. Effect of growth and differentiation factors on antigen-specific cell activation and production of monoclonal antibodies to autologous antigens and immunogens",
            "authors": [
                {
                    "first": "C.A.",
                    "middle": [],
                    "last": "Borrebaeck",
                    "suffix": ""
                },
                {
                    "first": "S.A.",
                    "middle": [],
                    "last": "M\u00f6ller",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "J. Immunol.",
            "volume": "136",
            "issn": "",
            "pages": "3710-3715",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Long-term human B cell lines dependent on interleukin-4 and antibody to CD40",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Banchereau",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "de Paoli",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Valle",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Garcia",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Rousset",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "Science",
            "volume": "251",
            "issn": "",
            "pages": "70-72",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus",
            "authors": [
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Traggiai",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Becker",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Subbarao",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Kolesnikova",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Uematsu",
                    "suffix": ""
                },
                {
                    "first": "M.R.",
                    "middle": [],
                    "last": "Gismondo",
                    "suffix": ""
                },
                {
                    "first": "B.R.",
                    "middle": [],
                    "last": "Murphy",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Rappuoli",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Lanzavecchia",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nat. Med.",
            "volume": "8",
            "issn": "",
            "pages": "871-875",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Development of a human adaptative immune system in cord blood cell-transplanted mice",
            "authors": [
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Traggiai",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Chicha",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Mazzucchelli",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Bronz",
                    "suffix": ""
                },
                {
                    "first": "J.C.",
                    "middle": [],
                    "last": "Piffaretti",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Lanzavecchia",
                    "suffix": ""
                },
                {
                    "first": "M.G.",
                    "middle": [],
                    "last": "Manz",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Science",
            "volume": "304",
            "issn": "",
            "pages": "104-107",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains",
            "authors": [
                {
                    "first": "S.L.",
                    "middle": [],
                    "last": "Morrison",
                    "suffix": ""
                },
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                },
                {
                    "first": "L.A.",
                    "middle": [],
                    "last": "Herzenberg",
                    "suffix": ""
                },
                {
                    "first": "V.T.",
                    "middle": [],
                    "last": "Oi",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "81",
            "issn": "",
            "pages": "6851-6855",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Variable-region identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Torres",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "May",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Scharff",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Casadevall",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J. Immunol.",
            "volume": "174",
            "issn": "",
            "pages": "2132-2142",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "A humanized antibody that binds to the interleukin 2 receptor",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Queen",
                    "suffix": ""
                },
                {
                    "first": "W.P.",
                    "middle": [],
                    "last": "Schneider",
                    "suffix": ""
                },
                {
                    "first": "H.E.",
                    "middle": [],
                    "last": "Selick",
                    "suffix": ""
                },
                {
                    "first": "P.W.",
                    "middle": [],
                    "last": "Payne",
                    "suffix": ""
                },
                {
                    "first": "N.F.",
                    "middle": [],
                    "last": "Landolfi",
                    "suffix": ""
                },
                {
                    "first": "J.F.",
                    "middle": [],
                    "last": "Duncan",
                    "suffix": ""
                },
                {
                    "first": "N.M.",
                    "middle": [],
                    "last": "Avdalovic",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Levitt",
                    "suffix": ""
                },
                {
                    "first": "R.P.",
                    "middle": [],
                    "last": "Junghans",
                    "suffix": ""
                },
                {
                    "first": "T.A.",
                    "middle": [],
                    "last": "Waldmann",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "86",
            "issn": "",
            "pages": "10029-10035",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Humanization of murine monoclonal antibodies through variable domain resurfacing",
            "authors": [
                {
                    "first": "M.A.",
                    "middle": [],
                    "last": "Roguska",
                    "suffix": ""
                },
                {
                    "first": "J.T.",
                    "middle": [],
                    "last": "Pedersen",
                    "suffix": ""
                },
                {
                    "first": "C.A.",
                    "middle": [],
                    "last": "Keddy",
                    "suffix": ""
                },
                {
                    "first": "A.H.",
                    "middle": [],
                    "last": "Henry",
                    "suffix": ""
                },
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Searle",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Lambert",
                    "suffix": ""
                },
                {
                    "first": "V.S.",
                    "middle": [],
                    "last": "Goldmacher",
                    "suffix": ""
                },
                {
                    "first": "W.A.",
                    "middle": [],
                    "last": "Blattler",
                    "suffix": ""
                },
                {
                    "first": "A.R.",
                    "middle": [],
                    "last": "Rees",
                    "suffix": ""
                },
                {
                    "first": "B.C.",
                    "middle": [],
                    "last": "Guild",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "91",
            "issn": "",
            "pages": "969-973",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda",
            "authors": [
                {
                    "first": "W.D.",
                    "middle": [],
                    "last": "Huse",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Sastry",
                    "suffix": ""
                },
                {
                    "first": "S.A.",
                    "middle": [],
                    "last": "Iverson",
                    "suffix": ""
                },
                {
                    "first": "A.S.",
                    "middle": [],
                    "last": "Kang",
                    "suffix": ""
                },
                {
                    "first": "M.M.",
                    "middle": [],
                    "last": "Alting",
                    "suffix": ""
                },
                {
                    "first": "D.R.",
                    "middle": [],
                    "last": "Burton",
                    "suffix": ""
                },
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Benkovic",
                    "suffix": ""
                },
                {
                    "first": "R.A.",
                    "middle": [],
                    "last": "Lerner",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "Science",
            "volume": "246",
            "issn": "",
            "pages": "1275-1281",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface",
            "authors": [
                {
                    "first": "G.P.",
                    "middle": [],
                    "last": "Smitth",
                    "suffix": ""
                }
            ],
            "year": 1985,
            "venue": "Science",
            "volume": "228",
            "issn": "",
            "pages": "1315-1317",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli",
            "authors": [
                {
                    "first": "J.S.",
                    "middle": [],
                    "last": "Huston",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Levinson",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Mudgett-Hunter",
                    "suffix": ""
                },
                {
                    "first": "M.S.",
                    "middle": [],
                    "last": "Tai",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Novotny",
                    "suffix": ""
                },
                {
                    "first": "M.N.",
                    "middle": [],
                    "last": "Margolies",
                    "suffix": ""
                },
                {
                    "first": "R.J.",
                    "middle": [],
                    "last": "Ridge",
                    "suffix": ""
                },
                {
                    "first": "R.E.",
                    "middle": [],
                    "last": "Bruccoleri",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Haber",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Crea",
                    "suffix": ""
                }
            ],
            "year": 1988,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "85",
            "issn": "",
            "pages": "5879-5883",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli",
            "authors": [
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Skerra",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Pl\u00fcckthun",
                    "suffix": ""
                }
            ],
            "year": 1988,
            "venue": "Science",
            "volume": "240",
            "issn": "",
            "pages": "1038-1041",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library",
            "authors": [
                {
                    "first": "T.J.",
                    "middle": [],
                    "last": "Vaughan",
                    "suffix": ""
                },
                {
                    "first": "A.J.",
                    "middle": [],
                    "last": "Williams",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Pritchard",
                    "suffix": ""
                },
                {
                    "first": "J.K.",
                    "middle": [],
                    "last": "Osbourn",
                    "suffix": ""
                },
                {
                    "first": "A.R.",
                    "middle": [],
                    "last": "Pope",
                    "suffix": ""
                },
                {
                    "first": "J.C.",
                    "middle": [],
                    "last": "Earnshaw",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "McCafferty",
                    "suffix": ""
                },
                {
                    "first": "R.A.",
                    "middle": [],
                    "last": "Hodits",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Wilton",
                    "suffix": ""
                },
                {
                    "first": "K.S.",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Nat. Biotechnol.",
            "volume": "14",
            "issn": "",
            "pages": "309-314",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "By-passing immunisation: human antibodies from synthetic repertoires of germline VH genes segments rearranged in vitro",
            "authors": [
                {
                    "first": "H.R.",
                    "middle": [],
                    "last": "Hoogenboom",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Winter",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "J. Mol. Biol.",
            "volume": "227",
            "issn": "",
            "pages": "381-388",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "A new phage display system to construct multicombinatorial libraries of very large antibody repertoires",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Geoffroy",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Sodoyer",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Aujame",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Gene",
            "volume": "151",
            "issn": "",
            "pages": "109-113",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Overview of antibody phage-display technology and its applications",
            "authors": [
                {
                    "first": "H.R.",
                    "middle": [],
                    "last": "Hoogenboom",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Methods Mol. Biol.",
            "volume": "178",
            "issn": "",
            "pages": "1-37",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Hanes",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Schaffitzel",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Knappik",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Pl\u00fcckthun",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Nat. Biotechnol.",
            "volume": "18",
            "issn": "",
            "pages": "1287-1292",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Yeast surface display for screening combinatorial polypeptide libraries",
            "authors": [
                {
                    "first": "E.T.",
                    "middle": [],
                    "last": "Boder",
                    "suffix": ""
                },
                {
                    "first": "K.D.",
                    "middle": [],
                    "last": "Wittrup",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Nat. Biotechnol.",
            "volume": "15",
            "issn": "",
            "pages": "553-558",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library",
            "authors": [
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Feldhaus",
                    "suffix": ""
                },
                {
                    "first": "R.W.",
                    "middle": [],
                    "last": "Siegel",
                    "suffix": ""
                },
                {
                    "first": "L.K.",
                    "middle": [],
                    "last": "Opresko",
                    "suffix": ""
                },
                {
                    "first": "J.R.",
                    "middle": [],
                    "last": "Coleman",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Feldhaus",
                    "suffix": ""
                },
                {
                    "first": "Y.A.",
                    "middle": [],
                    "last": "Yeung",
                    "suffix": ""
                },
                {
                    "first": "J.R.",
                    "middle": [],
                    "last": "Cochran",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Heinzelman",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Colby",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Swers",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Graff",
                    "suffix": ""
                },
                {
                    "first": "H.S.",
                    "middle": [],
                    "last": "Wiley",
                    "suffix": ""
                },
                {
                    "first": "K.D.",
                    "middle": [],
                    "last": "Wittrup",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Nat. Biotechnol.",
            "volume": "21",
            "issn": "",
            "pages": "163-170",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Antigen-specific human antibodies from mice comprising four distinct genetic modifications",
            "authors": [
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Lonberg",
                    "suffix": ""
                },
                {
                    "first": "L.D.",
                    "middle": [],
                    "last": "Taylor",
                    "suffix": ""
                },
                {
                    "first": "F.A.",
                    "middle": [],
                    "last": "Harding",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Trounstine",
                    "suffix": ""
                },
                {
                    "first": "K.M.",
                    "middle": [],
                    "last": "Higgins",
                    "suffix": ""
                },
                {
                    "first": "S.R.",
                    "middle": [],
                    "last": "Schramm",
                    "suffix": ""
                },
                {
                    "first": "C.C.",
                    "middle": [],
                    "last": "Kuo",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Mashayekh",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Wymore",
                    "suffix": ""
                },
                {
                    "first": "J.G.",
                    "middle": [],
                    "last": "McCabe",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Nature",
            "volume": "368",
            "issn": "",
            "pages": "856-859",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs",
            "authors": [
                {
                    "first": "L.L.",
                    "middle": [],
                    "last": "Green",
                    "suffix": ""
                },
                {
                    "first": "M.C.",
                    "middle": [],
                    "last": "Hardy",
                    "suffix": ""
                },
                {
                    "first": "C.E.",
                    "middle": [],
                    "last": "Maynard-Currie",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Tsuda",
                    "suffix": ""
                },
                {
                    "first": "D.M.",
                    "middle": [],
                    "last": "Louie",
                    "suffix": ""
                },
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Mendez",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Abderrahim",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Noguchi",
                    "suffix": ""
                },
                {
                    "first": "D.H.",
                    "middle": [],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Nat. Genet.",
            "volume": "7",
            "issn": "",
            "pages": "13-21",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Tomizuka",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Shinohara",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Yoshida",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Uejima",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Ohguma",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Sato",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Oshimura",
                    "suffix": ""
                },
                {
                    "first": "I.",
                    "middle": [],
                    "last": "Ishida",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Proc. Natl Acad. Sci. USA",
            "volume": "97",
            "issn": "",
            "pages": "722-727",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Intracellular expression of an antibody fragment neutralizing p21ras promotes tumor regression",
            "authors": [
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Cochet",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Kenigsberg",
                    "suffix": ""
                },
                {
                    "first": "I.",
                    "middle": [],
                    "last": "Delumeau",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Virone-Oddos",
                    "suffix": ""
                },
                {
                    "first": "M.-C.",
                    "middle": [],
                    "last": "Multon",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Fridman",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Schweighoffer",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Tocqu\u00e9",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Cancer Res.",
            "volume": "58",
            "issn": "",
            "pages": "1170-1176",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Caron de Fromentel",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Gruel",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Venot",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Debussche",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Conseiller",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Dureuil",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Tocqu\u00e9",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Bracco",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Oncogene",
            "volume": "18",
            "issn": "",
            "pages": "551-557",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc\u03b3RI bispecific antibody",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Michon",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Moutel",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Barbet",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Romet-Lemonne",
                    "suffix": ""
                },
                {
                    "first": "Y.M.",
                    "middle": [],
                    "last": "Deo",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Fridman",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Blood",
            "volume": "86",
            "issn": "",
            "pages": "1124-1130",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas",
            "authors": [
                {
                    "first": "J.L.",
                    "middle": [],
                    "last": "Teeling",
                    "suffix": ""
                },
                {
                    "first": "R.R.",
                    "middle": [],
                    "last": "French",
                    "suffix": ""
                },
                {
                    "first": "M.S.",
                    "middle": [],
                    "last": "Cragg",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "van den Brakel",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Pluyter",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "P.W.",
                    "middle": [],
                    "last": "Parren",
                    "suffix": ""
                },
                {
                    "first": "C.E.",
                    "middle": [],
                    "last": "Hack",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Dechant",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Valerius",
                    "suffix": ""
                },
                {
                    "first": "J.G.",
                    "middle": [],
                    "last": "van de Winkel",
                    "suffix": ""
                },
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Glennie",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Blood",
            "volume": "104",
            "issn": "",
            "pages": "1793-1800",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R",
            "authors": [
                {
                    "first": "R.L.",
                    "middle": [],
                    "last": "Shields",
                    "suffix": ""
                },
                {
                    "first": "A.K.",
                    "middle": [],
                    "last": "Namenuk",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Hong",
                    "suffix": ""
                },
                {
                    "first": "Y.G.",
                    "middle": [],
                    "last": "Meng",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Rae",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Briggs",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Lai",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Stadlen",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J.A.",
                    "middle": [],
                    "last": "Fox",
                    "suffix": ""
                },
                {
                    "first": "L.G.",
                    "middle": [],
                    "last": "Presta",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J. Biol. Chem.",
            "volume": "276",
            "issn": "",
            "pages": "6591-6604",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Umana",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Jean-Mairet",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Moudry",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Amstutz",
                    "suffix": ""
                },
                {
                    "first": "J.E.",
                    "middle": [],
                    "last": "Bailey",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Nat. Biotechnol.",
            "volume": "17",
            "issn": "",
            "pages": "176-180",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity",
            "authors": [
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Shinkawa",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Nakamura",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Yamane",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Shoji-Hosaka",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Kanda",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Sakurada",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Uchida",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Anazawa",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Satoh",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Yamasaki",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Hanai",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Shitara",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J. Biol. Chem.",
            "volume": "278",
            "issn": "",
            "pages": "3466-3473",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc\u03b3R functions",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Sib\u00e9ril",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "de Romeuf",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Bihoreau",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Fernandez",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Meterreau",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Regenman",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Nony",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Gaucher",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Glacet",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Jorieux",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Klein",
                    "suffix": ""
                },
                {
                    "first": "M.P.",
                    "middle": [],
                    "last": "Hogarth",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Fridman",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Bourel",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Beliard",
                    "suffix": ""
                },
                {
                    "first": "J.-L.",
                    "middle": [],
                    "last": "Teillaud",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Clin. Immunol.",
            "volume": "118",
            "issn": "",
            "pages": "170-179",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Therapeutic antibody production technologies: molecules, applications, expression and purification",
            "authors": [
                {
                    "first": "D.P.",
                    "middle": [],
                    "last": "Humphreys",
                    "suffix": ""
                },
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Glover",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Curr. Opin. Drug Discov. Devel.",
            "volume": "4",
            "issn": "",
            "pages": "172-185",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "Antibodies and genetically engineered related molecules: production and purification",
            "authors": [
                {
                    "first": "A.C.",
                    "middle": [],
                    "last": "Roque",
                    "suffix": ""
                },
                {
                    "first": "C.R.",
                    "middle": [],
                    "last": "Lowe",
                    "suffix": ""
                },
                {
                    "first": "M.A.",
                    "middle": [],
                    "last": "Taipa",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Biotechnol. Prog.",
            "volume": "20",
            "issn": "",
            "pages": "639-654",
            "other_ids": {
                "DOI": []
            }
        }
    }
}